ENGLEWOOD, Colo., Feb. 25, 2020 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced the U.S.
Food and Drug Administration ("FDA") granted 510(k) clearance for
sale in the U.S. for the CM-1500 Blood Volume Monitor.
Thomas Sandgaard, CEO said: "I am
very excited to finally have obtained FDA clearance to sell our
non-invasive Blood Volume Monitor in the U.S. The device is fully
developed, has performed well in multiple clinical trials and can
guide medical professionals in hospitals and surgical centers
towards better fluid management during surgery and in recovery
settings. Fluid management during and after surgery is one of the
largest un-met needs in hospitals today."
About Zynex, Inc.
Zynex, founded in 1996,
markets and sells its own design of electrotherapy medical devices
used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke
and spinal cord injury patients. Zynex is also developing a new
blood volume monitor for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains
forward-looking statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical
fact.
In some cases, you can identify forward-looking statements by
terminology, such as
"expects," "anticipates," "intends," "estimates," "plans," "believes," "seeks," "may," "should," "could," "will," "future," "projects," "strategy," or
the negative of such terms or other similar expressions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause actual results to materially differ from forward-looking
statements include, but are not limited to, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2018.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners,
LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-receives-fda-clearance-for-its-blood-volume-monitor-301010558.html
SOURCE Zynex